Kaur Harleen, Litinas Margarita-Chrissi, Lauder Christoper, Da Silva Nigel, Bradshaw Emma L, Price Timothy, Trochsler Markus, Wright Josephine, Woods Susan Lesley, Hewett Peter
Department of Surgery, The University of Adelaide, The Queen Elizabeth Hospital, Woodville, Australia.
Adelaide Medical School, The University of Adelaide, Adelaide, Australia.
ANZ J Surg. 2025 Jun 20. doi: 10.1111/ans.70214.
Pseudomyxoma peritonei (PMP) is a rare condition, often associated with a poor prognosis if left untreated. Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC), have emerged as the preferred treatment for this condition. The aim of this study was to report 22-year single centre outcomes for PMP following CRS and HIPEC.
A retrospective analysis of a prospectively maintained database (CALHN reference number: Q20160412) from 2002-2024 was conducted on all patients that underwent CRS and HIPEC for PMP at The Queen Elizabeth Hospital, Adelaide, South Australia (TQEH).
One hundred and twenty one CRS procedures were performed on 108 patients. Complete cytoreduction (CC0-1) was achieved in 85.9% cases. The overall median 3, 5 and 10-year survival rate for patients with PMP managed at TQEH was 70%, 55% and 23%, respectively. Among those who underwent HIPEC alongside CRS, the median survival was 92 months, with a 5-year survival rate of 62%. Median RFS was 109 months, with 61% 5-year RFS and 54% 10-year RFS. The 5-year survival rates for low-grade PMP and high-grade PMP without signet cells was 64.0% and 30.0%, respectively.
CRS and HIPEC is a safe and effective treatment for patients with PMP, demonstrating a 62% survival at 5 years. High-grade PMP histology and CEA ≥ 5 were independent predictors of worse OS. Our results demonstrate that comparable survival rates and recurrence free intervals to those reported by high-volume centres can be achieved, reinforcing the potential for successful outcomes in lower-volume settings while maintaining treatment quality and patient safety.
腹膜假黏液瘤（PMP）是一种罕见疾病，如果不治疗，通常预后较差。细胞减灭术（CRS）和热灌注化疗（HIPEC）已成为该疾病的首选治疗方法。本研究的目的是报告CRS和HIPEC治疗PMP 22年的单中心结局。
对2002年至2024年在南澳大利亚阿德莱德伊丽莎白女王医院（TQEH）接受CRS和HIPEC治疗PMP的所有患者，进行一项前瞻性维护数据库（CALHN参考编号：Q20160412）的回顾性分析。
对108例患者进行了121次CRS手术。85.9%的病例实现了完全细胞减灭（CC0 - 1）。在TQEH接受治疗的PMP患者的总体3年、5年和10年生存率分别为70%、55%和23%。在接受CRS联合HIPEC的患者中，中位生存期为92个月，5年生存率为62%。中位无复发生存期为109个月，5年无复发生存率为61%，10年无复发生存率为54%。低级别PMP和无印戒细胞的高级别PMP的5年生存率分别为64.0%和30.0%。
CRS和HIPEC是治疗PMP患者的一种安全有效的方法，5年生存率为62%。高级别PMP组织学和癌胚抗原（CEA）≥5是总生存期较差的独立预测因素。我们的结果表明，可以实现与大容量中心报告的相当的生存率和无复发生存期，这加强了在较小容量环境中取得成功结局的可能性，同时保持治疗质量和患者安全。
